SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : GZTC
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: biowa who wrote (356)7/13/1997 10:28:00 AM
From: Steve Push   of 752
 
GZTC is keeping a close eye on plant transgenics and hasn't ruled out the possibility of getting into this field in the future. However, plant transgenics is years behind animal transgenics, both scientifically and in the regulatory arena. It is not clear at this point that plants can ever be made to meet FDA's manufacturing standards. We already know that transgenic animals can meet these standards.

Glycosylation can be a very big isssue for some proteins, but not necessarily an insurmountable one. The glycosylation patten can be reworked after the protein is produced. We do this with Ceredase(R) and Cerezyme(R), in fact. But having to remodel the protein in this way will add cost to the process. It's always preferable to get the ideal glycosylation pattern from the start.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News